Amedisys Q1 2024 Earnings Report $84.47 +0.69 (+0.82%) (As of 12/20/2024 05:15 PM ET) Earnings HistoryForecast Amedisys EPS ResultsActual EPS$1.03Consensus EPS $1.02Beat/MissBeat by +$0.01One Year Ago EPS$1.00Amedisys Revenue ResultsActual Revenue$571.41 millionExpected Revenue$565.38 millionBeat/MissBeat by +$6.03 millionYoY Revenue Growth+2.70%Amedisys Announcement DetailsQuarterQ1 2024Date4/24/2024TimeAfter Market ClosesConference Call ResourcesSlide DeckPress ReleaseSEC FilingAMED Earnings HistorySlide DeckFull Screen Slide DeckPowered by Most People Are Dead Wrong. (Ad)Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.I call it my AI Retirement Playbook. I recommend you check it out now. Amedisys Earnings HeadlinesAmedisys (AMED) Down 12.4% Since Last Earnings Report: Can It Rebound?December 6, 2024 | finance.yahoo.comUnitedHealthcare CEO Fatally Shot a Month After US DOJ Sues Parent Company's £2.59B Takeover of AmedisysDecember 5, 2024 | msn.comWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.December 21, 2024 | Behind the Markets (Ad)UnitedHealthcare CEO gunned down in Manhattan sold company stocks just before DOJ probe made publicDecember 5, 2024 | msn.comMinnesota leaders respond after UnitedHealthcare CEO fatally shot in New York CityDecember 5, 2024 | msn.comDOJ launched probe into UnitedHealth for insider trading and attempted to stop monopolyDecember 5, 2024 | msn.comSee More Amedisys Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Amedisys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amedisys and other key companies, straight to your email. Email Address About AmedisysAmedisys (NASDAQ:AMED), together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.View Amedisys ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
